1 Di Fazio P,Waldegger P,Jabari S,et al.Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer[J].Oncotarget,2016,7(20):28998-29010. 2 Hwang KE,Kim YS,Jung JW,et al.Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells[J].Oncotarget,2015,6(30):29482-29496. 3 Lin L,Baehrecke EH.Autophagy,cell death,and cancer[J].Mol Cell Oncol,2015,2(3):e985913. 4 Rukkijakan T,Ngiwsara L,Lirdprapamongkol K,et al.A synthetic 2,3-diarylindole induces cell death via apoptosis and autophagy in A549 lung cancer cells[J].Bioorg Med Chem Lett,2016,26(9):2119-2123. 5 Jiang H,Cheng D,Liu W,et al.Protein kinase C inhibits autophagy and phosphorylates LC3[J].Biophys Res Commun,2010,395(4):471-476. 6 Dufour M,Dormond-Meuwly A,Pythoud C,et al.Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects[J].Biochem Biophys Res Commun,2013,438(1):32-37. 7 Grozinsky-Glasberg S,Rubinfeld H,Nordenberg Y,et al.The rapamycin-derivative RAD001(everolimus)inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells[J].Mol Cell Endocrinol,2010,315(1/2):87-94. 8 Molinolo AA,Marsh C,El Dinali M,et al.mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas[J].Clin Cancer Res,2012,18(9):2558-2568. 9 Oh KJ,Kalinina A,Park NH,et al.Deregulation of eIF4E:4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein[J].Clin Cancer Res,2006,80(14):7079-7088. 10 Faried LS,Faried A,Kanuma T,et al.Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix:A potential biomarker and molecular target therapy[J].Mol Carcinog,2008,47(6):446-457. 11 Faried LS,Faried A,Kanuma T,et al.Inhibition of the mammalian target of rapamycin(mTOR)by rapamycin increases chemosensitivity of CaSki cells to paclitaxel[J].Eur J Cancer,2006,42(7):934-947. 12 Redaelli S,Piazza R,Rostagno R,et al.Activity of bosutinib,dasatinib,and nilotinib against 18 imatinib-resistant BCR/ABL mutants[J].J Clin Oncol,2009,27(3):469-471. 13 Vajpai N,Strauss A,Fendrich G,et al.Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib[J].J Biol Chem,2008,283(3):18292-18302. 14 Tokunaga E,Oki E,Egashira A,et al.Deregulation of the Akt pathway in human cancer[J].Curr Cancer Drug Targets,2008,8(1):27-36. 15 Hu M,Ekshyyan O,Herman Ferdinandez L,et al.Efficacy and comparative effectiveness of sirolimus as an anticancer drug[J].Laryngoscope,2011,121(5):978-982. 16 潘小虹.自噬相关基因Beclin1和LC3Ⅱ在早期宫颈癌组织中的表达及临床意义[D].苏州:苏州大学,2012. 17 Sheng Y,Sun B,Guo WT,et al.3-Methyladenine induces cell death and its interaction with chemotherapeutic drugs is independent of autophagy[J].Biochem Biophys Res Commun,2013,432(1):5-9. |